aid: envisia
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/envisia.png
name: Envisia
description: >-
  Envisia (Envisia Therapeutics, Inc.) was a clinical-stage biopharmaceutical company based in
  Research Triangle Park, North Carolina, spun out of Liquidia Technologies to apply PRINT
  (Particle Replication In Non-wetting Templates) particle-engineering to sustained-release
  ophthalmic therapeutics. Its lead candidate, ENV515 (travoprost) extended-release, was an
  intracameral implant intended to lower intraocular pressure in glaucoma patients for months
  from a single administration. The company was venture-backed by Canaan Partners, New Enterprise
  Associates, Morningside, and Batterson Venture Capital, and was acquired by Aerie Pharmaceuticals
  in October 2016. As a therapeutics company it exposes no public developer, API, or documentation
  surface, and its former web domains no longer resolve; this profile is retained as a
  VC-portfolio lead record with no API artifacts to enrich.
url: https://raw.githubusercontent.com/api-evangelist/envisia/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Ophthalmology
- Drug Delivery
- Healthcare
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence